2022-501822-39-00招募中2 期
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progression
Philogen S.p.A.12 个研究点 分布在 3 个国家目标入组 113 人开始时间: 2023年2月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 113
- 试验地点
- 12
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Teresa Hemmerle
Scientific
Philogen S.p.A.
研究点 (12)
Loading locations...
相似试验
招募中
1 期
A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.2025-522243-17-00Philogen S.p.A.96
招募中
1 期
A study to evaluate the safety and tolerability of single ascending doses of AGMB-101 in healthy participants (Part A) and patients with liver cirrhosis (Part B).2024-515074-26-00AgomAb Therapeutics64
已完成
2 期
A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)2022-502057-33-00Sanofi-Aventis Recherche & Developpement59
已完成
1 期
A Study to Evaluate the Safety and Tolerability of JNJ-77730614 When Given as Single and Multiple Doses to Healthy Participants to Assess How Long JNJ 77730614 Stays in the Body (Pharmacokinetics) and How the Body Responds to it (Pharmacodynamics)2023-505684-36-00Janssen - Cilag International92
招募中
1 期
A study to assess the safety and immunogenicity of a therapeutic hepatitis B virus vaccine, in healthy adults (RUBY).Hepatitis B2025-521169-28-00AstriVax16